How common is acne with AndroGel specifically?

Clinical trial data for AndroGel report acne in approximately 3 to 6% of patients. This is lower than rates seen with injectable testosterone formulations, which produce higher peak androgen levels, but higher than background rates in adult men not on TRT.

Will my acne get worse before it gets better when I start topical retinoids?

Yes. A retinoid purge, meaning a temporary increase in comedones and papules in the first 2 to 4 weeks of tretinoin use, is expected as the medication accelerates turnover of pre-formed comedones to the surface. This is normal and resolves with continued use.

Can I use over-the-counter acne washes instead of prescription treatment?

For very mild comedonal acne, salicylic acid 2% washes or benzoyl peroxide 2.5 to 5% products are a reasonable starting point. If you see no meaningful improvement after 6 to 8 weeks, move to a prescription regimen. OTC products rarely adequately manage moderate or inflammatory acne driven by ongoing androgen stimulation.

Does the location where I apply AndroGel affect acne?

Possibly. Applying AndroGel to areas with high sebaceous gland density (upper chest, shoulders) may concentrate the local androgen effect and worsen acne at those sites. The FDA-approved application sites are shoulders, upper arms, and abdomen. Rotating away from areas where acne is active is a reasonable practical step.

Will lowering my AndroGel dose help my acne?

If your serum testosterone is above the target range (>950 to 1000 ng/dL), yes. Reducing the dose to bring levels into the mid-normal range (400 to 700 ng/dL) frequently reduces acne severity within 4 to 8 weeks. If your levels are already in range, dose reduction may not eliminate acne but may modestly reduce sebaceous stimulation.

How long do I need to treat acne caused by AndroGel?

As long as you remain on AndroGel, the androgen stimulus to sebaceous glands persists. This means topical maintenance therapy (typically benzoyl peroxide plus a retinoid) is often needed indefinitely. Systemic antibiotics should be time-limited to 3 to 6 months per course to minimize resistance risk.

Is there any TRT formulation less likely to cause acne than AndroGel?

The evidence is limited, but injectable testosterone formulations dosed every 2 weeks produce more pronounced peak-trough variation, which some clinicians believe worsens acne compared to daily transdermal delivery. Testosterone pellets produce stable levels and may be better tolerated by acne-prone patients, though head-to-head comparative acne data are sparse. This is a reasonable question to raise with your prescriber.

Can women or transgender patients on TRT also use this protocol?

The acne mechanism is the same regardless of the patient's sex or gender identity. The management protocol applies broadly to anyone using androgen therapy. Women and transgender men on testosterone therapy should note that some systemic acne medications, particularly doxycycline and isotretinoin, carry specific prescribing considerations, including pregnancy risk with isotretinoin covered by the iPLEDGE program.

When should I go to the emergency room for acne?

Acne itself is not an emergency, but a rapidly spreading skin infection (cellulitis) around acne lesions, characterized by expanding redness, warmth, fever, or red streaking, requires urgent evaluation. Severe nodulocystic acne with abscess formation may also require incision and drainage in an urgent care or dermatology setting.

Does diet affect testosterone-induced acne?

Diet alone is unlikely to resolve acne driven by exogenous androgen use. High-glycemic diets and dairy have modest evidence for worsening acne generally, per observational studies reviewed in the AAD guidelines03377-7/fulltext). Dietary modification is a reasonable adjunct but should not replace pharmacologic management in patients on TRT.

Managing Acne on AndroGel (testosterone topical): The HealthRX Step-by-Step Protocol

By HealthRX Medical Team

Published Jul 15, 2024Updated Jul 15, 2024Last reviewed Jul 15, 2024

Managing Acne on AndroGel (testosterone topical): The HealthRX Step-by-Step Protocol

At a glance

Incidence: 3 to 6% in phase III AndroGel trials; higher in patients with prior acne history or supratherapeutic testosterone levels
Typical onset: 4 to 12 weeks after initiating or up-titrating AndroGel
First-line management: Topical benzoyl peroxide 2.5 to 5% or topical retinoid (tretinoin 0.025 to 0.05%)
Escalation trigger: No improvement after 8 to 12 weeks of topical therapy, or moderate-to-severe inflammatory acne at presentation
Discontinuation signal: Nodulocystic or scarring acne unresponsive to systemic antibiotics plus optimized TRT dose; shared decision-making required
Key lab check: Serum total testosterone (trough and peak) to rule out supratherapeutic dosing as the driver

Why AndroGel Causes Acne: The Mechanism in Brief

Testosterone and its more potent metabolite dihydrotestosterone (DHT) bind androgen receptors in the pilosebaceous unit. This binding increases sebocyte proliferation, raises sebum production, and shifts the follicular microenvironment toward one that supports Cutibacterium acnes colonization. The result is comedonal and inflammatory acne, most commonly on the face, chest, upper back, and shoulders, which are the areas with the highest sebaceous gland density.

AndroGel delivers testosterone transdermally, producing a daily absorption profile that varies with application site, skin hydration, and inter-individual differences in skin permeability. Because serum testosterone fluctuates throughout the day after application, sebaceous glands are exposed to androgen peaks that may exceed the therapeutic window in some patients. The FDA prescribing information for AndroGel 1.62% acknowledges acne as a known adverse event in the reproductive and urinary system organ class, consistent with the broader androgen pharmacology.

The relationship between circulating androgen levels and acne severity is not perfectly linear. Even patients with testosterone levels in the normal physiologic range can develop acne if their sebaceous glands carry high local 5-alpha-reductase activity, which converts testosterone to the more potent DHT intracellularly. This means a serum testosterone level in range does not fully exclude TRT as the acne driver. The American Academy of Dermatology acne guidelines recognize androgen excess, including exogenous androgen use, as a contributing factor requiring targeted management.

Step 1: Assess Severity Before Choosing Treatment

The first clinical task is grading the acne. Treatment decisions at every step depend on severity grade, so a structured assessment at baseline saves time and prevents under-treatment.

Use the Global Acne Grading System (GAGS) or a simplified three-tier clinical classification:

Mild: Predominantly open and closed comedones (blackheads, whiteheads), fewer than 20 lesions total, no nodules
Moderate: 20, 100 mixed comedonal and inflammatory papules/pustules, possible small nodules (<5), limited scarring risk
Severe: >100 mixed lesions, multiple nodules or cysts, active scarring or sinus tracts

At baseline, also document:

Location (face, chest, back, shoulders)
Prior personal acne history before starting AndroGel
Current AndroGel dose and duration
Serum total testosterone level (most recent trough draw, ideally 2 to 4 hours post-application for peak, or just before next application for trough)
Any over-the-counter products already in use

This assessment directly determines which protocol step to start on. Patients presenting with severe acne at baseline skip Steps 2 and 3 and go straight to systemic therapy plus dermatology referral.

Step 2: Check Testosterone Levels First

Before any acne-specific treatment, verify that the patient is not running supratherapeutic testosterone levels. The Endocrine Society clinical practice guideline on testosterone therapy targets a serum total testosterone of 400 to 700 ng/dL (mid-normal range) for most hypogonadal men on TRT, with levels >1000 ng/dL considered supratherapeutic.

If total testosterone exceeds the upper limit of normal (>950 to 1000 ng/dL on most laboratory reference ranges), reduce the AndroGel dose before initiating acne treatment. Dose reduction alone frequently resolves or substantially reduces acne within 4 to 8 weeks by lowering the androgen stimulus to sebaceous glands. Recheck testosterone 2 to 4 weeks after dose adjustment to confirm the level has come down before concluding that acne is refractory.

If testosterone is within range, proceed to topical therapy without altering the AndroGel dose.

Step 3: First-Line Topical Therapy (Mild Acne)

For mild acne with testosterone levels in range, start with one or both of the following, depending on acne subtype.

Comedonal-predominant acne: Tretinoin 0.025% cream applied nightly to affected areas. Tretinoin normalizes follicular keratinization, the root cause of comedone formation. The vehicle and dose selection for topical retinoids matters: cream formulations cause less irritation than gels for patients new to retinoids. Expect a retinoid purge (transient worsening) in weeks 2, 4 before improvement begins. Full benefit takes 10 to 12 weeks.

Inflammatory papules and pustules: Benzoyl peroxide 2.5 to 5% gel or wash applied once daily. Benzoyl peroxide kills C. acnes by oxidative stress and does not generate antibiotic resistance, making it a durable first choice. The AAD acne guidelines list benzoyl peroxide as a first-line agent for inflammatory acne regardless of cause.

Combined presentation: Use both agents, but apply them at separate times (benzoyl peroxide in the morning, tretinoin at night) to avoid inactivation of tretinoin by peroxide oxidation.

Success at Step 3: >50% reduction in lesion count at 8 to 12 weeks, no new nodules, no scarring. Continue treatment and reassess every 3 months.

Failure at Step 3: <50% improvement at 12 weeks, development of new nodular lesions, or patient-reported significant impact on quality of life. Proceed to Step 4.

Step 4: Escalate to Topical Combination Therapy (Moderate Acne)

For moderate acne at presentation, or mild acne that failed Step 3, add a topical antibiotic or switch to a fixed-dose combination product.

Preferred combination: Clindamycin 1% plus benzoyl peroxide (fixed-dose gel, e.g., Benzaclin or generic equivalents). The pairing of an antibiotic with benzoyl peroxide limits the risk of antibiotic resistance by continuously reducing C. acnes counts even as antibiotic selection pressure is applied. A meta-analysis in the Journal of the American Academy of Dermatology confirmed that clindamycin-BPO combinations outperform either agent alone for inflammatory acne.

Add or continue tretinoin at night to address comedonal component and improve skin texture.

Do not use topical antibiotics as monotherapy. The AAD guidelines explicitly advise against antibiotic monotherapy for acne because of resistance development in resident skin flora.

Success at Step 4: Clear to nearly clear skin (>75% lesion reduction) at 12 weeks. Transition to benzoyl peroxide plus retinoid maintenance; discontinue topical antibiotic after 3 to 4 months.

Failure at Step 4: Persistent moderate acne after 12 weeks of combination topical therapy, or any appearance of nodules or cysts. Proceed to Step 5.

Step 5: Systemic Therapy (Moderate-to-Severe or Refractory Acne)

Systemic antibiotics are appropriate for inflammatory acne that has not responded to optimized topical regimens or for moderate-to-severe acne at initial presentation.

First choice: Doxycycline 100 mg once daily. Doxycycline has anti-inflammatory properties beyond its antimicrobial activity and is well-tolerated in most adults. The subantimicrobial-dose doxycycline data suggest that anti-inflammatory effects contribute substantially to efficacy even below bactericidal concentrations, though standard 100 mg dosing is used for moderate-to-severe disease.

Alternative: Minocycline 100 mg once daily. Avoid in patients with renal impairment. Both doxycycline and minocycline carry a prescribing caution for patients on concurrent medications affecting the QT interval, though this is rarely a concern in otherwise healthy men on TRT.

Limit systemic antibiotic duration to 3 to 6 months. Always co-prescribe benzoyl peroxide throughout the course to reduce resistance emergence. Reassess at 8 to 12 weeks.

Success at Step 5: Significant clearance (>75% reduction) with no new scarring lesions. Step down to topical maintenance after completing the antibiotic course.

Failure at Step 5: Persistent nodular or cystic acne after one complete antibiotic course, or relapse within 4 to 6 weeks of stopping antibiotics. This is the threshold for dermatology referral and isotretinoin discussion.

Step 6: Dermatology Referral and Isotretinoin Consideration

Any patient with nodulocystic acne, acne causing scarring, or acne refractory to two systemic antibiotic courses requires formal dermatology referral. Isotretinoin (oral 13-cis-retinoic acid) remains the only treatment capable of producing long-term remission in severe acne by suppressing sebaceous gland activity at the gland level. The landmark isotretinoin mechanism review in NEJM established that 0.5 to 1 mg/kg/day for 4 to 6 months produces sustained remission in >80% of severe acne patients.

Isotretinoin and AndroGel can be used concurrently, but the prescribing dermatologist should be informed about TRT use. Hepatotoxicity risk is additive with other hepatically metabolized medications, and lipid monitoring (triglycerides, LDL) is required during isotretinoin therapy. The iPLEDGE program requirements apply to all isotretinoin prescribers and patients in the United States.

At this stage, re-evaluate whether AndroGel itself should be dose-reduced or substituted with an alternative TRT delivery method (e.g., intramuscular testosterone cypionate dosed every 2 weeks, which produces different peak-trough kinetics). Some patients find that moving to a less frequent, more predictable dosing schedule reduces the sebaceous stimulus compared to daily transdermal exposure.

When to Discontinue AndroGel for Acne

Discontinuation of AndroGel for acne alone is rare but appropriate in the following situations:

Nodulocystic acne with active scarring that persists after isotretinoin (i.e., acne returns when isotretinoin is stopped while TRT continues)
Patient preference after informed discussion about the tradeoff between TRT benefits and acne burden
Contraindication to isotretinoin (e.g., hypertriglyceridemia) in a patient with severe, scarring acne

If discontinuation occurs for acne management, the Endocrine Society guideline recommends reassessing hypogonadism symptoms and testosterone levels 3 to 6 months after stopping TRT before deciding whether a different formulation or delivery method is appropriate.

Frequently asked questions

›

References

AbbVie. AndroGel 1.62% (testosterone gel) full prescribing information. FDA. Updated 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202763s016lbl.pdf
Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715, 1744. https://academic.oup.com/jcem/article/103/5/1715/4939465
Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2024. https://www.jaad.org/article/S0190-9622(23)03377-7/fulltext
Doshi A, Zaheer A, Stiller MJ. A comparative study of current acne grading systems and proposal of a novel system. Int J Dermatol. 1997;36(6):416, 418. https://pubmed.ncbi.nlm.nih.gov/9764843/
Leyden JJ, Del Rosso JQ. The impact of the use of benzoyl peroxide in preventing the emergence of antibiotic resistance in topical acne therapy. J Drugs Dermatol. 2004;3(4):423, 431. https://pubmed.ncbi.nlm.nih.gov/12789175/
Strauss JS, Krowchuk DP, Leyden JJ, et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol. 2007;56(4):651, 663.
Skidmore R, Kovach R, Walker C, et al. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol. 2003;139(4):459, 464. https://pubmed.ncbi.nlm.nih.gov/12780794/
Thiboutot D. Acne: hormonal concepts and therapy. Clin Dermatol. 2004;22(5):419, 428. https://pubmed.ncbi.nlm.nih.gov/16517571/
Layton AM. The use of isotretinoin in acne. Dermatoendocrinol. 2009;1(3):162, 169. https://pubmed.ncbi.nlm.nih.gov/9709066/
iPLEDGE Program. Prescriber and patient information. https://www.ipledgeprogram.com/
Zouboulis CC. Acne and sebaceous gland function. Clin Dermatol. 2004;22(5):360, 366. https://pubmed.ncbi.nlm.nih.gov/15475226/
Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003;49(1 Suppl):S1, S37. https://pubmed.ncbi.nlm.nih.gov/12833004/
Del Rosso JQ, Kim GK. Optimizing use of oral antibiotics in acne vulgaris. Dermatol Clin. 2009;27(1):33, 42. https://pubmed.ncbi.nlm.nih.gov/30124398/